Go to
current issue
-
Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life Eur. Urol. (IF 25.3) Pub Date : 2024-12-19 Marie-Pier St-Laurent, Bernard Bochner, James Catto, Benjamin J. Davies, Christian Daniel Fankhauser, Tullika Garg, Jill Hamilton-Reeves, Viraj Master, Bente T. Jensen, Susanne V. Lauridsen, Elizabeth Wulff-Burchfield, Sarah P. Psutka
Background and objectiveTreatment burden refers to the overall impact of medical treatments on a patient’s well-being and daily life. Our objective is to evaluate the impact of treatment burden on quality of life (QoL) in patients with genitourinary (GU) malignancies, highlighting the importance of patient-reported outcomes (PROs) in clinical trials to inform treatment decisions and improve patient
-
Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum Eur. Urol. (IF 25.3) Pub Date : 2024-12-18 Johan Stranne, Ann Henry, Daniela E. Oprea-Lager
No Abstract
-
Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease? Eur. Urol. (IF 25.3) Pub Date : 2024-12-17 Steven Tisseverasinghe, Marwan Tolba, Fred Saad, Karim Fizazi, Boris Bahoric, Tamim Niazi
No Abstract
-
The Discrepancy Between Patient-reported Outcomes, Adverse Events, and Radiographic Progression-free Survival in MAGNITUDE and Other Recent Trials Eur. Urol. (IF 25.3) Pub Date : 2024-12-17 Celestia S. Higano
No Abstract
-
Biparametric Versus Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Choice or a Fine Balance? Eur. Urol. (IF 25.3) Pub Date : 2024-12-16 Adriano B. Dias, Caroline M. Moore, Raphaële Renard-Penna, Francesco Giganti
No Abstract
-
Clinical Implementation of Minimal Residual Disease Testing in Genitourinary Cancers: Bridging Promise and Practice Eur. Urol. (IF 25.3) Pub Date : 2024-12-13 Rana R. McKay, Joshua Lang, Himisha Beltran
No Abstract
-
-
-
-
Balancing Efficacy and Cardiotoxicity in Prostate Cancer Therapy: A Call for Precision in Treatment Strategies Eur. Urol. (IF 25.3) Pub Date : 2024-12-12 Omar El-Taji, Noel W. Clarke
High-risk, potentially lethal prostate cancer (PCa) requires systemic androgen deprivation therapy (ADT), with doublet therapy offering superior anticancer effects in comparison to monotherapy, and triplet therapy being more effective than doublet. However, nothing comes without a cost. In the review of such combination therapies by Aziz et al [1] in this issue of European Urology, the authors endeavour
-
-
Multiparametric Magnetic Resonance Imaging with Targeted-only Biopsy—A New Standard for Guidelines on Prostate Cancer Detection? Eur. Urol. (IF 25.3) Pub Date : 2024-12-12 John W. Davis
No Abstract
-
Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update Eur. Urol. (IF 25.3) Pub Date : 2024-12-11 Elizabeth J. Schafer, Mathieu Laversanne, Hyuna Sung, Isabelle Soerjomataram, Alberto Briganti, William Dahut, Freddie Bray, Ahmedin Jemal
Background and objectiveOur aim was to examine worldwide patterns and trends for prostate cancer (PC) incidence and mortality using high-quality, up-to-date, population-based data. MethodsWe analyzed age-standardized PC incidence and mortality rates by country and region from the 2022 GLOBOCAN estimates and temporal trends in incidence (50 countries/territories) and mortality (59 countries/territories)
-
-
-
-
-
-
-
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers Eur. Urol. (IF 25.3) Pub Date : 2024-12-05 Pedro C. Barata, Kevin K. Zarrabi, Axel Bex, Petros Grivas, Ken Hermann, Michael S. Hofman, Roger Li, Antonio Lopez-Beltran, Anwar R. Padani, Thomas Powles, Mary-Ellen Taplin, Yohann Loriot
Background and objectiveAdvances in molecular diagnostics have ushered in a new era for patients with prostate, renal, and urothelial cancers, with novel radiographic and molecular modalities for the assessment of disease burden and minimal residual disease (MRD). Conventional imaging has a limited threshold for disease detection and is often unable to discern clinically occult disease with varying
-
Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial Eur. Urol. (IF 25.3) Pub Date : 2024-12-04 Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, Bob-Valéry Occéan, Nadine Houédé, Arnauld Villers, Pascal Rischmann
Background and objectiveHigh-intensity focused ultrasound (HIFU) has emerged as an interesting ablative alternative to radical prostatectomy (RP) and radiation therapy (RT) for localized prostate cancer (PC). However, no prospective comparative data have been published for HIFU. MethodsWe performed a prospective nonrandomized nationwide trial in 46 centers in France comparing RP versus HIFU. The main
-
Genomic Classifiers To Guide Postprostatectomy Radiation Therapy: An Opening Movement in G-MINOR Eur. Urol. (IF 25.3) Pub Date : 2024-11-30 Scott Eggener, Stanley L. Liauw
No Abstract
-
Can a Molecular Classifier of Upper Tract Urothelial Carcinoma Inform Clinical Decision-making and Biological Stratification? Eur. Urol. (IF 25.3) Pub Date : 2024-11-30 Marie-Pier St-Laurent, Jussi Nikkola, Henning Bahlburg, Joshua M. Scurll, Peter C. Black
No Abstract
-
Re: Risk Factors for Artificial Urinary Sphincter Explantation and Erosion in Male Nonneurological Patients Eur. Urol. (IF 25.3) Pub Date : 2024-11-30 Daniel S. Elliott
No Abstract
-
Despite an Abundance of Active Treatment Options for Renal Cell Carcinoma, Shadows Still Obscure the Light Eur. Urol. (IF 25.3) Pub Date : 2024-11-29 Camillo Porta, Carlo Ganini, Mimma Rizzo
No Abstract
-
Re: Transperineal vs Transrectal Prostate Biopsy—The PREVENT Randomized Clinical Trial Eur. Urol. (IF 25.3) Pub Date : 2024-11-27 Truls E. Bjerklund Johansen, Tommaso Cai, Per-Henrik Zahl
No Abstract
-
Re: Prevalence and Factors Associated with Prostate Cancer Among Transgender Women Eur. Urol. (IF 25.3) Pub Date : 2024-11-22 François-Xavier Madec, Benoît Mesnard, Charles Dariane
No Abstract
-
Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study Eur. Urol. (IF 25.3) Pub Date : 2024-11-22 Matthew R. Cooperberg
No Abstract
-
Re: Adjuvant Pembrolizumab Versus Observation in Muscle-Invasive Urothelial Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2024-11-22 Keiichiro Mori, Takahiro Kimura, Shahrokh F. Shariat
No Abstract
-
Expanding the Reach of FGFR Inhibitors to Advance Precision Medicine in Urothelial Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2024-11-22 Vadim S. Koshkin, Guru P. Sonpavde
No Abstract
-
Radiopharmaceuticals in Genitourinary Cancers: A Fast-evolving Field with a Bright Perspective Eur. Urol. (IF 25.3) Pub Date : 2024-11-21 Irene A. Burger, John Babich
No Abstract
-
Population-based Screening for Prostate Cancer: Is it Time? Eur. Urol. (IF 25.3) Pub Date : 2024-11-20 Jonas Hugosson
No Abstract
-
Re: Comprehensive Evaluation of the Ability of Comorbidity and Health Status Indices to Improve the Prediction of Perioperative Morbidity and Long-term Survival Outcomes After Radical Cystectomy Eur. Urol. (IF 25.3) Pub Date : 2024-11-16 Alexander Lloyd, Patrick Y. Wuethrich, Christopher Soliman, Marc A. Furrer
No Abstract
-
Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-11-16 Philipp Dahm, Timothy J. Wilt
No Abstract
-
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2024-11-16 Kwanghee Kim, Syed M. Alam, Fengshen Kuo, Ziyu Chen, Wesley Yip, Andrew B. Katims, Carissa Chu, Andrew T. Lenis, Wenhuo Hu, Gamze Gokturk Ozcan, Jie-Fu Chen, Sanaz Firouzi, Yuval Elhanati, Timothy N. Clinton, Andreas Aulitzky, Nima Almassi, Yoich Fujii, Andrew T. Tracey, Peter A. Reisz, Sadna Budhu, Lynda Vuong, Jordan Eichholz, Hyung Jun Woo, Lucas Nogueira, Sizhi P. Gao, Avigdor Scherz, David H.
Molecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed multi-omic analysis of UTUC tumors to identify molecular features associated with disease recurrence and response to immune checkpoint blockade (ICB).
-
Re: Adhesive Anti-fibrotic Interfaces on Diverse Organs Eur. Urol. (IF 25.3) Pub Date : 2024-11-14 David D’Andrea, Shahrokh F. Shariat
No Abstract
-
Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review Eur. Urol. (IF 25.3) Pub Date : 2024-11-13 Valentina Tateo, Zachary J. Thompson, Scott M. Gilbert, Victoria K. Cortessis, Siamak Daneshmand, Timothy A. Masterson, Darren R. Feldman, Phillip M. Pierorazio, Gagan Prakash, Axel Heidenreich, Peter Albers, Andrea Necchi, Philippe E. Spiess
Background and objectiveTesticular germ cell tumors (TGCTs) are globally rare, although incidence significantly varies across global geographic regions and ethnicities. Recent decades have seen an unexplained increase in incidence. This review investigates the changing epidemiology of TGCT and identifies key risk factors. MethodsA systematic review following the Preferred Reporting Items for Systematic
-
Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial Eur. Urol. (IF 25.3) Pub Date : 2024-11-13 Amar U. Kishan, James M. Lamb, Holly Wilhalme, Maria Casado, Natalie Chong, Lily Zello, Jesus E. Juarez, Tommy Jiang, Beth K. Neilsen, Daniel A. Low, Yingli Yang, John Neylon, Vincent Basehart, Ting Martin Ma, Luca F. Valle, Minsong Cao, Michael L. Steinberg
It has been shown that magnetic resonance imaging (MRI) guidance versus computed tomography (CT) guidance for aggressive margin-reduction (AMR) for stereotactic body radiotherapy (SBRT) in prostate cancer reduces acute toxicity, but the longer-term benefits are unknown. We performed a secondary analysis of MIRAGE, a phase 3 randomized clinical trial of MRI-guided SBRT for prostate cancer, to determine
-
Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen Deprivation Therapy in the RADICALS-HD Randomised Trial Eur. Urol. (IF 25.3) Pub Date : 2024-11-12 Pirus Ghadjar, Daniel Zips
No Abstract
-
-
-
-
-
Corrigendum to “Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)” [Eur Urol. 86(1) (2024) 52–60] Eur. Urol. (IF 25.3) Pub Date : 2024-11-09 Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, Tristan R. Grogan, David Elashoff, Ethan C. Lam, Kevyn J. Clark, Michael L. Steinberg, Wolfgang P. Fendler, Thomas A. Hope, Nicholas G. Nickols, Johannes Czernin, Jeremie Calais
The authors regret about typological errors in the article found by Feng Qi as published in the letter to the editor of July 25, 2024 in European Urology.
-
First and Second-line Treatments in Metastatic Renal Cell Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2024-11-06 Regina Barragan-Carrillo, Eddy Saad, Renee-Maria Saliby, Maxine Sun, Laurence Albiges, Axel Bex, Daniel Heng, Arnaud Mejean, Robert J. Motzer, Elizabeth R. Plimack, Thomas Powles, Brian I. Rini, Tian Zhang, Toni K. Choueiri
Background and objectiveThe treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of this review is to provide clinicians with a practical guide for selecting first- and second-line treatments on the basis of current evidence. MethodsWe critically evaluated systemic treatment strategies for mRCC. A comprehensive
-
Re: Maarten De Rooij, Clare Allen, Jasper J. Twilt, et al. PI-QUAL Version 2: An Update of a Standardised Scoring System for the Assessment of Image Quality of Prostate MRI. Eur Radiol. In press. https://doi.org/10.1007/s00330-024-10795-4 Eur. Urol. (IF 25.3) Pub Date : 2024-11-01 Geert Villeirs, Valeria Panebianco, Caroline M. Moore, Jelle O. Barentsz
No Abstract
-
Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection Eur. Urol. (IF 25.3) Pub Date : 2024-10-29 Karim A. Touijer, Emily A. Vertosick, Daniel D. Sjoberg, Nicole Liso, Sunny Nalavenkata, Barbara Melao, Vincent P. Laudone, Behfar Ehdaie, Brett Carver, James A. Eastham, Peter T. Scardino, Andrew J. Vickers
Background and objectiveLymph node dissection (LND) has been standard in cancer surgery for more than a century, yet evidence from randomized trials showing a benefit is scarce. We conducted a clinically integrated randomized trial comparing limited versus extended pelvic LND (PLND) during radical prostatectomy and previously reported comparable biochemical recurrence (BCR) rates. We report updated
-
Challenges and Considerations in Modern Adjuvant Therapy Trials in Renal Cell Carcinoma: A Call to Power Eur. Urol. (IF 25.3) Pub Date : 2024-10-29 Daniel D. Shapiro, Pavlos Msaouel
No Abstract
-
Best Practice in Using Social Media: The European Association of Urology Position Statement Eur. Urol. (IF 25.3) Pub Date : 2024-10-29 Jeremy Yuen-Chun Teoh, Nikita R. Bhatt, Vito Cucchiara, Esther Garcia Rojo, Vineet Gauhar, Claudia Mercader, Benjamin Pradere, Wesley Verla, Julie Darraugh, Carla Bezuidenhout, Marc van Gurp, Elisabeth Hesston, Jarka Bloemberg, James N’Dow, Maria J. Ribal, Gianluca Giannarini
Section snippets General principles for SoMe useThere are ten general principles that urologists should follow when using SoMe platforms (Fig. 1) [1]. Physicians should clearly state their role and align their online behavior with professional standards. It is essential to protect patient privacy by avoiding identifiable information and discussing treatment details only with explicit consent. To prevent
-
Transporting Testosterone Home: Navigating the Road to Recovery Eur. Urol. (IF 25.3) Pub Date : 2024-10-29 Vedang Murthy, Alan Dal Pra
Prostate cancer treatment has been significantly shaped by the use of androgen deprivation therapy (ADT) in combination with definitive radiotherapy. Modern approaches, including gonadotropin-releasing hormone (GnRH) agonists and antagonists and novel androgen receptor pathway inhibitors (ARPIs), have refined testosterone suppression techniques, improving outcomes for both metastatic and nonmetastatic
-
What’s in a Name? Why Words Matter in Advanced Prostate Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-10-29 William K. Oh, Neeraj Agarwal, Alan Bryce, Pedro Barata, Courtney Bugler, Sigrid V. Carlsson, Brad Cornell, William Dahut, Daniel George, Stacy Loeb, Bruce Montgomery, David Morris, Lorelei A. Mucci, Aurelius Omlin, Ganesh Palapattu, Irbaz Bin Riaz, Charles Ryan, Martin W. Schoen, Samuel L. Washington III, Silke Gillessen
Section snippets Metastatic hormone-sensitive prostate cancer (mHSPC)The debate concerning the scientific accuracy and negative connotations of the word “castration” for patients has been discussed previously [3], [4] and is clearly a prominent example of the powers—positive and negative—mentioned above. In particular, we believe that the word “castration” is difficult for patients, partners, and families
-
Re: Natural History of Histologically Benign PIRADS 4–5 Lesions in Multiparametric MRI: Real-life Experience in an Academic Center Eur. Urol. (IF 25.3) Pub Date : 2024-10-24 Vincenzo Ficarra, Gabriele Sorce, Marta Rossanese, Ettore Di Trapani
No Abstract
-
Reply to Roger L. Sur’s Letter to the Editor re: Frédéric Panthier, Vineet Gauhar, Eugenio Ventimiglia, Jia-Lun Kwok, Etienne Xavier Keller, Olivier Traxer. Rethinking Stone-free Rates and Surgical Outcomes in Endourology: A Point of View from PEARLS Members. Eur Urol 2024;86:198–9 Eur. Urol. (IF 25.3) Pub Date : 2024-10-23 Frédéric Panthier, Bhaskar Somani, Olivier Traxer
No Abstract
-
Re: [89Zr]Zr-Girentuximab for PET–CT Imaging of Clear-cell Renal Cell Carcinoma: A Prospective, Open-label, Multicentre, Phase 3 Trial Eur. Urol. (IF 25.3) Pub Date : 2024-10-22 Riccardo Campi, Alessio Pecoraro, Salvatore Granata, Sergio Serni
No Abstract
-
Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study Eur. Urol. (IF 25.3) Pub Date : 2024-10-22 Jasper J. Twilt, Anindo Saha, Joeran S. Bosma, Bram van Ginneken, Anders Bjartell, Anwar R. Padhani, David Bonekamp, Geert Villeirs, Georg Salomon, Gianluca Giannarini, Jayashree Kalpathy-Cramer, Jelle Barentsz, Klaus H. Maier-Hein, Mirabela Rusu, Olivier Rouvière, Roderick van den Bergh, Valeria Panebianco, Veeru Kasivisvanathan, Nancy A. Obuchowski, Derya Yakar, Maarten de Rooij
Background and objectiveBiparametric magnetic resonance imaging (bpMRI), excluding dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), is a potential replacement for multiparametric MRI (mpMRI) in diagnosing clinically significant prostate cancer (csPCa). An extensive international multireader multicase observer study was conducted to assess the noninferiority of bpMRI to mpMRI in csPCa
-
Sensitive Detection of Urothelial Cancer via High-volume Urine DNA Analysis Eur. Urol. (IF 25.3) Pub Date : 2024-10-22 Jussi Nikkola, Lauri Ryyppö, Juuso Vuorinen, Heini Kallio, Hanna Selin, Pyry Jämsä, Jonne Åkerla, Tuomo Virtanen, Tarmo Pekkarinen, Antti Kaipia, Johanna Pulkkinen, Gillian Vandekerkhove, David C. Müller, Alexander W. Wyatt, Peter C. Black, Matti Nykter, Thea Veitonmäki, Matti Annala
Cystoscopy and imaging are the gold standard for urothelial cancer (UC) detection and surveillance, but cystoscopy is an uncomfortable procedure with a low diagnostic yield, as only 10% of patients with hematuria have UC [1]. Urine tumor DNA (utDNA) is a noninvasive UC biomarker that has historically suffered from poor sensitivity for Ta stage tumors (<80%) (Supplementary Table 1). We hypothesized
-
Re: Ex Vivo Surgical Removal Versus Conservative Management of Small Asymptomatic Kidney Stones in Living Donors and Long Term Kidney Transplant Outcomes Eur. Urol. (IF 25.3) Pub Date : 2024-10-20 Emilien Seizilles de Mazancourt, Paul Meria
No Abstract
-
Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers Eur. Urol. (IF 25.3) Pub Date : 2024-10-20 Martina Sollini, Jeremie Calais, Arturo Chiti, Louise Emmett, Stefano Fanti, Wolfgang Fendler, Ken Herrmann, Thomas A. Hope, Oliver Sartor, Brian Shuch, Scott Tagawa, Michael S. Hofman
Background and objectiveThis review aims to provide an overview of novel diagnostic and therapeutic radiopharmaceuticals tested recently or used currently in genitourinary cancers within prospective phase 1–2 clinical trials, summarizing progresses and future directions. MethodsA systematic search was conducted using the PubMed/MEDLINE and ClinicalTrials.gov databases for original prospective research
-
Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-10-19 Wolfgang P. Fendler, Viktor Grünwald, Ken Herrmann, Boris A. Hadaschik
No Abstract
-
Advancing Prostate Cancer Care: Prostate-specific Membrane Antigen–based Radioligand Therapy at the Forefront Eur. Urol. (IF 25.3) Pub Date : 2024-10-19 Laura Evangelista, Luigi Cecchi, Paolo Andrea Zucali
No Abstract
更新日期：2024-12-20
Copyright © 2014-2024 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号